LLC Innovative Pharmacology Research, Tomsk, Russia.
Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia.
Bull Exp Biol Med. 2022 Apr;172(6):709-712. doi: 10.1007/s10517-022-05461-y. Epub 2022 May 2.
New antithrombotic drug GRS, a soluble guanylate cyclase stimulator, after repeated administration in a dose of 10 mg/kg alleviates the symptoms of endothelial dysfunction in rats with myocardial infarction; it restores antiplatelet activity of the blood vessel wall and vasodilatory function of the endothelium without producing significant effect on endothelium-independent vasodilation. GRS also has direct antiaggregant and antihypertensive effects in therapeutic doses. The obtained data suggest that GRS can be therapeutically useful in patients with cardiovascular diseases accompanied by endothelial dysfunction.
新型抗血栓药物 GRS，一种可溶性鸟苷酸环化酶刺激剂，在 10mg/kg 的剂量下重复给药可缓解心肌梗死大鼠的内皮功能障碍症状；它恢复了血管壁的抗血小板活性和内皮的血管舒张功能，而对内皮非依赖性血管舒张没有显著影响。GRS 在治疗剂量下还具有直接的抗聚集和降压作用。获得的数据表明，GRS 可在伴有内皮功能障碍的心血管疾病患者中具有治疗用途。
